The role of conventional and novel PET radiotracers in assessment of myeloma bone disease Review
| Author: | Zirakchian Zadeh, M. |
| Review Title: | The role of conventional and novel PET radiotracers in assessment of myeloma bone disease |
| Abstract: | Over 80 % of patients with multiple myeloma (MM) experience osteolytic bone lesions, primarily due to an imbalanced interaction between osteoclasts and osteoblasts. This imbalance can lead to several adverse outcomes such as pain, fractures, limited mobility, and neurological impairments. Myeloma bone disease (MBD) raises the expense of management in addition to being a major source of disability and morbidity in myeloma patients. Whole-body x-ray radiography was the gold standard imaging modality for detecting lytic lesions. Osteolytic lesions are difficult to identify at an earlier stage on X-ray since the lesions do not manifest themselves on conventional radiographs until at least 30 % to 50 % of the bone mass has been destroyed. Hence, early diagnosis of osteolytic lesions necessitates the utilization of more complex and advanced imaging modalities, such as PET. One of the PET radiotracers that has been frequently investigated in MM is 18F-FDG, which has demonstrated a high level of sensitivity and specificity in detecting myeloma lesions. However, 18F-FDG PET/CT has several restrictions, and therefore the novel PET tracers that can overcome the limitations of 18F-FDG PET/CT should be further examined in assessment of MBD. The objective of this review article is to thoroughly examine the significance of both conventional and novel PET radiotracers in the assessment of MBD. The intention is to present the information in a manner that would be easily understood by healthcare professionals from diverse backgrounds, while minimizing the use of complex nuclear medicine terminology. Copyright © 2023 Elsevier Inc. All rights reserved. |
| Keywords: | positron emission tomography; radiopharmaceuticals; multiple myeloma; tomography, x-ray computed; pathology; diagnostic imaging; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; radiopharmaceutical agent; bone disease; bone diseases; bone turnover; procedures; osteolytic lesions; humans; human; x-ray computed tomography; positron emission tomography-computed tomography; positron emission tomography computed tomography; pathologic fractures |
| Journal Title: | Bone |
| Volume: | 179 |
| ISSN: | 8756-3282 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-02-01 |
| Start Page: | 116957 |
| Language: | English |
| DOI: | 10.1016/j.bone.2023.116957 |
| PUBMED: | 37972747 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work